MNTA Momenta Pharmaceuticals Inc.

12.64
0  0%
Previous Close 12.64
Open
Price To Book 2.95
Market Cap 1,246,449,651
Shares 98,611,523
Volume 0
Short Ratio
Av. Daily Volume 432,994

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial met primary endpoint - November 29, 2016.
M923
Moderate-to-severe chronic plaque psoriasis
Filed 2007. Approved April 16 2015.
Generic Copaxone
Multiple sclerosis
Phase 2 development discontinued due to poor efficacy shown
Necuparanib (MOM-M402-103)
Advanced metastatic pancreatic cancer
Phase 1 trial to be completed 2019.
M230 (CSL730)
Healthy volunteers
Phase 2 data due 2020.
M281
generalized myasthenia gravis (gMG)
Phase 2 data due 2021.
M281
hemolytic disease of the fetus and newborn (HDFN)
Phase 1/2 dosing has commenced - noted January 29, 2019. Initial data due 1H 2020.
M254
Immune Thrombocytopenic Purpura (ITP)

Latest News

  1. Momenta Pharmaceuticals Announces Settlement Agreement with Amphastar Resolving Enoxaparin Sodium Injection Litigation
  2. See what the IHS Markit Score report has to say about Momenta Pharmaceuticals Inc.
  3. Did You Manage To Avoid Momenta Pharmaceuticals's (NASDAQ:MNTA) 47% Share Price Drop?
  4. Momenta Pharmaceuticals to Webcast Presentation at the Goldman Sachs 40th Annual Global Healthcare Conference
  5. Momenta (MNTA) Down 16.6% Since Last Earnings Report: Can It Rebound?
  6. Edited Transcript of MNTA earnings conference call or presentation 2-May-19 12:30pm GMT
  7. Momenta Pharmaceuticals to Webcast Presentation at the 2019 Bank of America Merrill Lynch Healthcare Conference
  8. Momenta Pharmaceuticals Wants to Be the "Humira of the FcRn Space"
  9. Hedge Funds Have Never Been This Bullish On Momenta Pharmaceuticals, Inc. (MNTA)
  10. Momenta Pharmaceuticals Inc (MNTA) Q1 2019 Earnings Call Transcript
  11. Momenta Pharmaceuticals (MNTA) Reports Q1 Loss, Misses Revenue Estimates
  12. Momenta: 1Q Earnings Snapshot
  13. Momenta Pharmaceuticals Reports First Quarter 2019 Financial and Operating Results
  14. Momenta Pharmaceuticals (MNTA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
  15. Momenta Pharmaceuticals Announces Date of First Quarter 2019 Financial Results Conference Call and Webcast
  16. New Research Coverage Highlights American International Group, Fox Factory Holding, Momenta Pharmaceuticals, Mercer International, Endurance International Group, and Addus HomeCare — Consolidated Revenues, Company Growth, and Expectations for 2019